US2010197764A1PendingUtilityA1
Antisense modulation of acyl coa cholesterol acyltransferase-2 expression
Est. expiryJul 30, 2021(expired)· nominal 20-yr term from priority
A61P 9/10A61P 9/00C12N 2310/3341C12Y 203/01026C12N 2310/315C12N 15/1137C12N 2310/321A61P 3/00A61K 38/00C12N 2310/341C12N 2310/346Y02P20/582
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of acyl CoA cholesterol acyltransferase-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding acyl CoA cholesterol acyltransferase-2. Methods of using these compounds for modulation of acyl CoA cholesterol acyltransferase-2 expression and for treatment of diseases associated with expression of acyl CoA cholesterol acyltransferase-2 are provided.
Claims
exact text as granted — not AI-modified1 . A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding acyl CoA cholesterol acyltransferase-2, wherein said compound specifically hybridizes with and inhibits the expression of a nucleic acid molecule encoding acyl CoA cholesterol acyltransferase-2.
2 . The compound of claim 1 which is an antisense oligonucleotide.
3 . The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 21, 23, 24, 25, 26, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38, 42, 43, 46, 47, 48, 49, 54, 55, 56, 57, 58, 62, 63 or 65.
4 . The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
5 . The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6 . The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
7 . The compound of claim 6 wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.
8 . The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
9 . The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
10 . The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
11 . A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding acyl CoA cholesterol acyltransferase-2.
12 . A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
13 . The composition of claim 12 further comprising a colloidal dispersion system.
14 . The composition of claim 12 wherein the compound is an antisense oligonucleotide.
15 . A method of inhibiting the expression of acyl CoA cholesterol acyltransferase-2 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of acyl CoA cholesterol acyltransferase-2 is inhibited.
16 . A method of treating an animal having a disease or condition associated with acyl CoA cholesterol acyltransferase-2 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of acyl CoA cholesterol acyltransferase-2 is inhibited.
17 . The method of claim 16 wherein the condition involves abnormal lipid metabolism.
18 . The method of claim 16 wherein the condition involves abnormal cholesterol metabolism.
19 . The method of claim 16 wherein the condition is atherosclerosis.
20 . The method of claim 16 wherein the disease is cardiovascular disease.Join the waitlist — get patent alerts
Track US2010197764A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.